Male Breast Cancer Completed Phase 2 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00119262Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerTreatment